Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HARVARD BIOSCIENCE INC
Report date July 07, 2019 · Filed July 09, 2019
Section 16 reporting ended · disclosed 2019-07-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 464,528 |
Reported balance
After 2019-07-07 transaction · row 1
1 source rowRow 1 · 2019-07-07 · Disposition to issuer · Disposed 285,473 · Balance 464,528 F1: The following restricted stock units were forfeited as a result of the Reporting Person's separation of service from the Issuer effective as of July 7, 2019: (a) 89,402 restricted stock units granted to the Reporting Person on May 25, 2017; (b) 47,222 restricted stock units granted to the Reporting Person on May 24, 2018; (c) 7,556 restricted stock units granted to the Reporting Person on May 24, 2018 that related to an award with a performance condition tied to relative total shareholder return; (d) 84,776 restricted stock units granted to the Reporting Person on March 7, 2019; and (e) restricted stock units, with a target amount of 56,517, granted to the Reporting Person on March 7, 2019 contingent upon achievement of a performance condition tied to relative total shareholder return. |
Filing footnotes · ownership attribution and instrument terms
F1: The following restricted stock units were forfeited as a result of the Reporting Person's separation of service from the Issuer effective as of July 7, 2019: (a) 89,402 restricted stock units granted to the Reporting Person on May 25, 2017; (b) 47,222 restricted stock units granted to the Reporting Person on May 24, 2018; (c) 7,556 restricted stock units granted to the Reporting Person on May 24, 2018 that related to an award with a performance condition tied to relative total shareholder return; (d) 84,776 restricted stock units granted to the Reporting Person on March 7, 2019; and (e) restricted stock units, with a target amount of 56,517, granted to the Reporting Person on March 7, 2019 contingent upon achievement of a performance condition tied to relative total shareholder return.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2019 Filed Jul 9, 2019 20:18 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Disposition to issuerCommon Stock | 285,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-041549 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,528 F1 · shares: The following restricted stock units were forfeited as a result of the Reporting Person's separation of service from the Issuer effective as of July 7, 2019: (a) 89,402 restricted stock units granted to the Reporting Person on May 25, 2017; (b) 47,222 restricted stock units granted to the Reporting Person on May 24, 2018; (c) 7,556 restricted stock units granted to the Reporting Person on May 24, 2018 that related to an award with a performance condition tied to relative total shareholder return; (d) 84,776 restricted stock units granted to the Reporting Person on March 7, 2019; and (e) restricted stock units, with a target amount of 56,517, granted to the Reporting Person on March 7, 2019 contingent upon achievement of a performance condition tied to relative total shareholder return. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 20:06 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | OtherCommon Stock | 3,334 | $1.70 | $5,667.80 |
DisclosureSEC source: 0001209191-19-039695 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,001 F1 · kind: Represents shares acquired under the Issuer's Employee Stock Purchase Plan. F2 · price: Represents the purchase price for each share purchased under the Employee Stock Purchase Plan and equals 85% of the fair market value of common stock on June 28, 2019, being the exercise date under the plan. F3 · balance_after: Includes (a) a deferred stock award of 56,517 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on March 7, 2020, 2021 and 2022, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 113,034 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023; (c) a deferred stock award of 70,833 restricted stock units which vest in equal installments on January 1, 2020, 2021 and 2022; (d) a deferred stock award of 178,804 restricted stock units which shall vest in equal installments on January 1, 2020 and 2021; (e) a deferred stock award of 72,916 restricted stock units which shall vest on January 1, 2020; F4 · balance_after: continuation of footnote 3 above: (f) a deferred stock award of 7,556 restricted stock units, which vest in equal installments on May 24, 2020 and May 24, 2021; and (g) 250,341 shares of common stock held by the Reporting Person. Read SEC document |
| May 24, 2019 Filed May 29, 2019 21:07 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 1,111 | $2.31 | $2,566.41 |
DisclosureSEC source: 0001209191-19-033245 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 746,667 F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain restricted stock units previously granted to the Reporting Person on May 24, 2018. F2 · balance_after: Includes (a) a deferred stock award of 56,517 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on March 7, 2020, 2021 and 2022, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 113,034 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023; (c) a deferred stock award of 70,833 restricted stock units which vest in equal installments on January 1, 2020, 2021 and 2022; (d) a deferred stock award of 178,804 restricted stock units which shall vest in equal installments on January 1, 2020 and 2021; (e) a deferred stock award of 72,916 restricted stock units which shall vest on January 1, 2020; F3 · balance_after: continuation of footnote 2 above: (f) a deferred stock award of 7,556 restricted stock units, which vest in equal installments on May 24, 2020 and May 24, 2021; and (g) 247,007 shares of common stock held by the Reporting Person. With respect to the performance based deferred stock award received on May 24, 2018, the Reporting Person had previously included the target number of such award, being 94,444 shares, in his reported holdings, and on May 24, 2019, the actual earned award amount was determined to be 11,333. As such, the 83,111 shares previously reported but not earned are no longer included in the securities beneficially owned. Read SEC document |
| April 12, 2019 Filed Apr 12, 2019 20:06 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 400 | $4.65 | $1,860.00 |
DisclosureSEC source: 0001209191-19-024470 · doc4.xml · nonDerivative · entry 3 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,888 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · balance_after: Includes the awards referenced in clauses (a) through (f) of footnotes (3) and (4) above, plus 244,340 shares of common stock held by the Reporting Person. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 20:06 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 12,425 | $4.51 | $56,036.75 |
DisclosureSEC source: 0001209191-19-024470 · doc4.xml · nonDerivative · entry 2 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 831,288 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5). F6 · balance_after: Includes the awards referenced in clauses (a) through (f) of footnotes (3) and (4) above, plus 244,740 shares of common stock held by the Reporting Person. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 20:06 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 6,332 | $4.50 | $28,494.00 |
DisclosureSEC source: 0001209191-19-024470 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 843,713 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). F3 · balance_after: Includes (a) a deferred stock award of 56,517 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on March 7, 2020, 2021 and 2022, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 113,034 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023; (c) a deferred stock award of 70,833 restricted stock units which vest in equal installments on January 1, 2020, 2021 and 2022; (d) a deferred stock award of 178,804 restricted stock units which shall vest in equal installments on January 1, 2020 and 2021; (e) a deferred stock award of 72,916 restricted stock units which shall vest on January 1, 2020; F4 · balance_after: continuation of footnote 3 above: (f) a deferred stock award of 94,444 restricted stock units with performance based vesting conditions, which if earned shall vest in equal installments on May 24, 2019, 2020 and 2021, and are contingent upon achievement of a performance condition tied to relative shareholder return; and (g) 257,165 shares of common stock held by the Reporting Person. Read SEC document |
| March 07, 2019 Filed Apr 2, 2019 20:56 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantStock option (right to buy) · Derivative | 271,139 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001209191-19-022619 · doc4.xml · derivative · entry 3 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,139 Underlying: Common Stock, par value $0.01 per share · 271,139 shares Expires 2029-03-07 F5 · derivative.exercise_date: The options vest in four equal installments on January 1, 2020, 2021, 2022 and 2023. Read SEC document |
| March 07, 2019 Filed Apr 2, 2019 20:56 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 56,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-022619 · doc4.xml · nonDerivative · entry 2 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,045 F3 · shares: Represents a deferred stock award of 56,517 restricted stock units with performance based vesting conditions. These restricted stock units shall vest in equal installments on March 7, 2020, 2021 and 2022, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from March 7, 2019 to the earlier of (i) March 7, 2020 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date). The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported. F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, and (b) the award described in footnote (3) above. Read SEC document |
| March 07, 2019 Filed Apr 2, 2019 20:56 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 113,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-022619 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 793,528 F1 · shares: Represents a deferred stock award of 113,034 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023. F2 · balance_after: Includes (a) a deferred stock award of 113,034 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023; (b) a deferred stock award of 70,833 restricted stock units which vest in equal installments on January 1, 2020, 2021 and 2022; (c) a deferred stock award of 178,804 restricted stock units which shall vest in equal installments on January 1, 2020 and 2021; (d) a deferred stock award of 72,916 restricted stock units which shall vest on January 1, 2020; (e) a deferred stock award of 94,444 restricted stock units with performance based vesting conditions, which if earned shall vest in equal installments on May 24, 2019, 2020 and 2021, and are contingent upon achievement of a performance condition tied to relative total shareholder return; and (f) 263,497 shares of common stock held by the Reporting Person. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:12 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 61,755 | $3.18 | $196,380.90 |
DisclosureSEC source: 0001209191-19-000905 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 680,494 F1 · shares: The shares were disposed to satisfy the Reporting Person's tax withholding obligation in connection with deferred stock awards previously granted to the Reporting Person which vested in part on January 1, 2019. F2 · balance_after: Includes (a) a deferred stock award of 94,444 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 70,833 restricted stock units which shall vest in three equal installments on January 1, 2020, 2021 and 2022; (c) a deferred stock award of 178,804 restricted stock units which shall vest in three equal installments on January 1, 2020 and 2021; (d) a deferred stock award of 72,916 restricted stock units which shall vest on January 1, 2020; and (e) 263,497 shares of common stock held by the Reporting Person. Read SEC document |
| August 09, 2018 Filed Aug 9, 2018 21:00 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 44,500 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-18-046059 · doc4.xml · derivative · entry 9 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock, par value $0.01 per share · 394,500 shares Expires 2023-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 09, 2018 Filed Aug 9, 2018 21:00 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 44,500 | $6.41 | $285,245.00 |
DisclosureSEC source: 0001209191-18-046059 · doc4.xml · nonDerivative · entry 6 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 790,742 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.35 to $6.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9). F5 · balance_after: Includes the awards referenced in clauses (a) through (f) of footnotes (2) and (3) above plus 98,842 shares of common stock held by the Reporting Person. Read SEC document |
| August 09, 2018 Filed Aug 9, 2018 21:00 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 44,500 | $4.31 | $191,795.00 |
DisclosureSEC source: 0001209191-18-046059 · doc4.xml · nonDerivative · entry 5 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · balance_after: Includes the awards referenced in clauses (a) through (f) of footnotes (2) and (3) above plus 143,342 shares of common stock held by the Reporting Person. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 21:00 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 5,500 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-18-046059 · doc4.xml · derivative · entry 8 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,500 Underlying: Common Stock, par value $0.01 per share · 400,000 shares Expires 2013-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 21:00 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 5,500 | $6.35 | $34,925.00 |
DisclosureSEC source: 0001209191-18-046059 · doc4.xml · nonDerivative · entry 4 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 790,742 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.35 to $6.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7). F5 · balance_after: Includes the awards referenced in clauses (a) through (f) of footnotes (2) and (3) above plus 98,842 shares of common stock held by the Reporting Person. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 21:00 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 5,500 | $4.31 | $23,705.00 |
DisclosureSEC source: 0001209191-18-046059 · doc4.xml · nonDerivative · entry 3 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 796,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · balance_after: Includes the awards referenced in clauses (a) through (f) of footnotes (2) and (3) above plus 104,342 shares of common stock held by the Reporting Person. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 21:00 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-18-046059 · doc4.xml · derivative · entry 7 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock, par value $0.01 per share · 500,000 shares Expires 2023-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 21:00 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 100,000 | $6.07 | $607,000.00 |
DisclosureSEC source: 0001209191-18-046059 · doc4.xml · nonDerivative · entry 2 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 790,742 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.15 to $6.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4). F5 · balance_after: Includes the awards referenced in clauses (a) through (f) of footnotes (2) and (3) above plus 98,842 shares of common stock held by the Reporting Person. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 21:00 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 100,000 | $4.31 | $431,000.00 |
DisclosureSEC source: 0001209191-18-046059 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes (a) a deferred stock award of 94,444 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 94,444 restricted stock units which shall vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (c) a deferred stock award of 268,206 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (d) a deferred stock award of 145,833 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (e) a deferred stock award of 17,225 restricted stock units which shall vest in full on January 1, 2019; (continued in footnote 3 below) F3 · balance_after: (continuation of footnote 3 above) (f) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (g) 198,842 shares of common stock held by the Reporting Person. Read SEC document |
| August 03, 2018 Filed Aug 13, 2018 20:09 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 12,619 | $5.70 | $71,928.30 |
DisclosureSEC source: 0001209191-18-046402 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742,249 F1 · shares: The shares were disposed to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain restricted stock units previously granted to the Reporting Person on August 3, 2015. F2 · balance_after: Includes (a) a deferred stock award of 94,444 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 94,444 restricted stock units which shall vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (c) a deferred stock award of 268,206 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (d) a deferred stock award of 145,833 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (e) a deferred stock award of 17,225 restricted stock units which shall vest in full on January 1, 2019; and (f) 122,097 shares of common stock held by the Reporting Person. Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 00:12 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 14,205 | $5.22 | $74,150.10 |
DisclosureSEC source: 0001209191-18-042406 · doc4.xml · nonDerivative · entry 3 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 790,742 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.175 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7). F8 · balance_after: Includes the awards referenced in clauses (a) through (f) of footnotes (3) and (4) above plus 98,842 shares of common stock held by the Reporting Person. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 00:12 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 11,600 | $5.38 | $62,408.00 |
DisclosureSEC source: 0001209191-18-042406 · doc4.xml · nonDerivative · entry 2 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 804,947 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.28 to $5.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5). F6 · balance_after: Includes the awards referenced in clauses (a) through (f) of footnotes (3) and (4) above plus 113,047 shares of common stock held by the Reporting Person. Read SEC document |
| July 09, 2018 Filed Jul 12, 2018 00:12 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 14,195 | $5.41 | $76,794.95 |
DisclosureSEC source: 0001209191-18-042406 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,547 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.38 to $5.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). F3 · balance_after: Includes (a) a deferred stock award of 94,444 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 94,444 restricted stock units which shall vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (c) a deferred stock award of 268,206 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (d) a deferred stock award of 145,833 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (e) a deferred stock award of 17,225 restricted stock units which shall vest in full on January 1, 2019; F4 · balance_after: continuation of footnote 3 above) (f) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (g) 124,647 shares of common stock held by the Reporting Person. Read SEC document |
| May 24, 2018 Filed May 29, 2018 20:23 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 94,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033824 · doc4.xml · nonDerivative · entry 2 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,742 F3 · shares: Represents a deferred stock award of 94,444 restricted stock units with performance based vesting conditions. These restricted stock units shall vest in three equal annual installments on May 24, 2019, May 24, 2020 and May 24, 2021, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from May 24, 2018 to the earlier of (i) May 24, 2019 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date). The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported. F4 · balance_after: Includes (a) a deferred stock award of 94,444 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; and (b) all awards and common stock held by the Reporting Person as described in footnote 2 above. Read SEC document |
| May 24, 2018 Filed May 29, 2018 20:23 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 94,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033824 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 736,298 F1 · shares: Represents a deferred stock award of 94,444 restricted stock units which shall vest in four equal installments on January 1, 2019, 2020, 2021 and 2022. F2 · balance_after: Includes (a) a deferred stock award of 94,444 restricted stock units which shall vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (b) a deferred stock award of 268,206 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (c) a deferred stock award of 145,833 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (d) a deferred stock award of 17,225 restricted stock units which shall vest in full on January 1, 2019; (e) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (f) 138,842 shares of common stock held by the Reporting Person. Read SEC document |
| March 09, 2018 Filed Mar 12, 2018 21:25 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 7,800 | $4.60 | $35,880.00 |
DisclosureSEC source: 0001209191-18-018911 · doc4.xml · nonDerivative · entry 2 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 641,854 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.60 to $4.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · balance_after: Includes (a) a deferred stock award of 268,206 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (b) a deferred stock award of 145,833 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (c) a deferred stock award of 17,225 restricted stock units which shall vest in full on January 1, 2019; (d) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (e) 138,842 shares of common stock held by the Reporting Person. Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 21:25 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 79,222 | $4.52 | $358,083.44 |
DisclosureSEC source: 0001209191-18-018911 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,654 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · balance_after: Includes (a) a deferred stock award of 268,206 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (b) a deferred stock award of 145,833 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (c) a deferred stock award of 17,225 restricted stock units which shall vest in full on January 1, 2019; (d) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (e) 146,642 shares of common stock held by the Reporting Person. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 13:49 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 60,108 | $3.30 | $198,356.40 |
DisclosureSEC source: 0001209191-18-001628 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,876 F1 · shares: The shares were disposed to satisfy the Reporting Person's tax withholding obligation in connection with deferred stock awards previously granted to the Reporting Person which vested in part on January 1, 2018. F2 · balance_after: Includes (a) a deferred stock award of 268,206 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (b) a deferred stock award of 145,833 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (c) a deferred stock award of 17,225 restricted stock units which shall vest in full on January 1, 2019; (d) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (e) 225,864 shares of common stock held by the Reporting Person. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:03 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 22,000 | $2.66 | $58,520.00 |
DisclosureSEC source: 0001209191-17-039532 · doc4.xml · nonDerivative · entry 2 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788,984 F3 · price: This transaction was executed in multiple trades at prices ranging from $2.65 to $2.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: Includes (a) a deferred stock award of 357,609 restricted stock units which shall vest in four equal installments on January 1, 2018, 2019, 2020 and 2021; (b) a deferred stock award of 218,750 restricted stock units which shall vest in three equal installments on January 1, 2018, 2019 and 2020; (c) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018 and 2019; (d) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (e) 106,427 shares of common stock held by the Reporting Person. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:03 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | PurchaseCommon Stock | 22,000 | $2.76 | $60,720.00 |
DisclosureSEC source: 0001209191-17-039532 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,984 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.70 to $2.80. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes (a) a deferred stock award of 357,609 restricted stock units which shall vest in four equal installments on January 1, 2018, 2019, 2020 and 2021; (b) a deferred stock award of 218,750 restricted stock units which shall vest in three equal installments on January 1, 2018, 2019 and 2020; (c) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018 and 2019; (d) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (e) 128,427 shares of common stock held by the Reporting Person. Read SEC document |
| May 25, 2017 Filed May 31, 2017 00:36 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 357,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036298 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788,984 F1 · shares: Represents a deferred stock award of 357,609 restricted stock units which shall vest in four equal installments on January 1, 2018, 2019, 2020 and 2021. F2 · balance_after: Includes (a) a deferred stock award of 357,609 restricted stock units which shall vest in four equal installments on January 1, 2018, 2019, 2020 and 2021; (b) a deferred stock award of 218,750 restricted stock units which shall vest in three equal installments on January 1, 2018, 2019 and 2020; (c) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018 and 2019; (d) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (e) 106,427 shares of common stock held by the Reporting Person. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 22:11 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 31,248 | $3.05 | $95,306.40 |
DisclosureSEC source: 0001209191-17-001160 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,375 F1 · shares: The shares were disposed to satisfy the Reporting Person's tax withholding obligation in connection with deferred stock awards previously granted to the Reporting Person which vested in part on January 1, 2017. F2 · balance_after: Includes (a) a deferred stock award of 218,750 restricted stock units which shall vest in three equal installments on January 1, 2018, 2019 and 2020; (b) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018 and 2019; (c) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (c) 106,427 shares of common stock held by the Reporting Person. Read SEC document |
| November 03, 2016 Filed Nov 3, 2016 20:12 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | PurchaseCommon Stock | 15,000 | $2.42 | $36,300.00 |
DisclosureSEC source: 0001209191-16-148159 · doc4.xml · nonDerivative · entry 1 Duchemin Jeffrey · CIK 0001585223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,623 F1 · price: This transaction was executed in several trades between $2.35 and $2.50. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes (a) a deferred stock award of 291,667 restricted stock units which shall vest in four equal installments on January 1, 2017, 2018, 2019 and 2020; (b) a deferred stock award of 51,675 restricted stock units which shall vest in three equal installments on January 1, 2017, 2018 and 2019; (c) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (c) 47,533 shares of common stock held by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.